Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors

Details for Australian Patent Application No. 2009251024 (hide)

Owner Antisense Pharma GmbH

Inventors Schlingensiepen, Reimar; Schlingensiepen, Karl-Hermann

Agent Davies Collison Cave

Parent 2006243218

Filing date 18 December 2009

Event Publications

7 January 2010 Complete Application Filed

21 January 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  Application withdrawn under section 141(1). Examination has not yet been requested or directed for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009251025-Hay bale stacker

2009251023-Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors